SEC Form 4 · accession 0000899243-18-019720
Global Blood Therapeutics, Inc. · GBT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Deval L Patrick
Director
Period of report
Jul 6, 2018
Accepted (ET)
Jul 10, 2018 · 6:13 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001629137
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jul 6, 2018 | M | 15,000 | $28.45 | A | 15,000 | D | |
| Common Stock | Jul 6, 2018 | M | 15,000 | $20.00 | A | 30,000 | D | |
| Common Stock | Jul 6, 2018 | M | 8,361 | $20.00 | A | 38,361 | D | |
| Common Stock | Jul 6, 2018 | M | 4,018 | $3.40 | A | 42,379 | D | |
| Common StockF1 | Jul 6, 2018 | S | 42,379 | $43.4008 | D | 0 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (right to buy)F2 | $28.45 | Jul 6, 2018 | M | 15,000 | D | — | Jun 19, 2027 | Common Stock | 15,000 | 0 | D |
| Employee Stock Option (right to buy)F3 | $20.00 | Jul 6, 2018 | M | 15,000 | D | — | Aug 10, 2025 | Common Stock | 15,000 | 0 | D |
| Employee Stock Option (right to buy)F4 | $20.00 | Jul 6, 2018 | M | 8,361 | D | — | Aug 20, 2025 | Common Stock | 8,361 | 239 | D |
| Employee Stock Option (right to buy)F5 | $3.40 | Jul 6, 2018 | M | 4,018 | D | — | Apr 8, 2025 | Common Stock | 4,018 | 5,357 | D |
Explanation of responses
- F1Represents the weighted average sale price of the shares sold ranging from $43.35 to $43.85 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.
- F2The shares subject to this option shall vest and become exercisable in 12 equal monthly installments with the first installment on July 20, 2017, subject to the recipient's continued service on the Issuer's Board of Directors, such that this option became fully exercisable on June 20, 2018. This option is subject to accelerated vesting upon a change of control of the Issuer.
- F3The shares subject to this option shall vest and become exercisable in 12 equal monthly installments with the first installment on September 11, 2015, such that this option became fully exercisable on August 11, 2016. This option is subject to accelerated vesting upon a change of control of the Issuer.
- F4The shares subject to this option shall vest and become exercisable in 36 equal monthly installments with the first installment on August 23, 2015, such that this option is fully exercisable on July 23, 2018. This option is subject to accelerated vesting upon a change of control of the Issuer.
- F525% of the shares subject to this option vested and became exercisable on April 8, 2016, and the remaining shares subject to this option shall vest and become exercisable in 12 equal quarterly installments thereafter.